circPDSS1通过靶向miR-1298调控肝癌细胞侵袭、迁移和凋亡的分子机制

肝脏 ›› 2021, Vol. 26 ›› Issue (9): 1011-1015.

circPDSS1通过靶向miR-1298调控肝癌细胞侵袭、迁移和凋亡的分子机制

李敏, 吴兴桂, 朱军华

430400 武汉湖北省中山医院阳逻院区普外科(李敏);湖北省第三人民医院普外科(吴兴桂,朱军华)

收稿日期:2020-10-31 出版日期:2021-09-30 发布日期:2021-10-22
通讯作者: 朱军华,Email:vdu708@163.com

circPDSS1 regulates the invasion, migration and apoptosis of hepatocellular carcinoma cells by targeting miR-1298

LI Min¹, WU Xing-gui², ZHU Jun-hua²

1. Department of General Surgery, Yangluo Hospital District, Zhongshan Hospital of Hubei Province, Wuhan 430400, China;
2. Department of General Surgery, the Third People's Hospital of Hubei Province, Wuhan 430050, China

Received:2020-10-31 Online:2021-09-30 Published:2021-10-22
Contact: ZHU Jun-hua,Email:vdu708@163.com

摘要/Abstract

摘要： 目的探讨环状RNA PDSS1(circPDSS1)对肝癌细胞凋亡、迁移和侵袭的影响及其机制。方法实时荧光定量PCR(RT-qPCR)检测肝癌组织、癌旁组织中circPDSS1和miR-1298的表达。双荧光素酶报告基因实验、RT-qPCR确定circPDSS1对miR-1298的靶向调控作用。将circPDSS1小干扰RNA(si-circPDSS1)、miR-1298 mimics、si-circPDSS1+ miR-1298抑制物(anti-miR-1298)分别转染肝癌细胞MHCC97H,流式细胞术检测细胞凋亡,Transwell实验检测细胞迁移和侵袭。结果与癌旁组织比较,肝癌组织中circPDSS1表达(3.41±0.33比1.00±0.06)显著升高,miR-1298表达(0.42±0.04比1.00±0.07)显著降低(P<0.05)。circPDSS1对miR-1298具有靶向负性调控作用。抑制circPDSS1表达后MHCC97H细胞凋亡率(22.71±2.19比6.02±0.05)显著升高,迁移(55.72±4.78比101.86±9.65)和侵袭(41.24±3.80比85.71±7.57)细胞数显著减少(P<0.05)。过表达miR-1298后MHCC97H细胞凋亡率(18.67±1.06 vs 7.08±0.69)显著升高,迁移(61.11±5.54比107.15±10.96)和侵袭(50.05±4.22比88.57±7.96)细胞数显著减少(P<0.05)。与抑制circPDSS1比较,同时抑制miR-1298和circPDSS1后MHCC97H细胞凋亡率(11.68±1.24比23.31±2.84)显著减低,迁移(86.59±7.44比54.59±4.78)和侵袭(76.01±6.33比39.91±3.73)细胞数显著增加(P<0.05)。结论抑制circPDSS1表达能够降低肝癌细胞的迁移和侵袭能力,诱导细胞凋亡,其机制与靶向调控miR-1298有关。

关键词: circPDSS1, 肝癌, 迁移侵袭, 凋亡, miR-1298

Abstract: Objective To investigate the effect of circular RNA PDSS1 (circPDSS1) on apoptosis, migration and invasion of liver cancer cells and its mechanism. Methods The expression of circPDSS1 and miR-1298 in liver cancer tissues and adjacent tissues were detected by real-time fluorescence quantitative PCR (RT-qPCR). Dual luciferase reporter gene experiment and RT-qPCR were used to confirm the targeted regulation of circPDSS1 on miR-1298. CircPDSS1 small interfering RNA (si-circPDSS1), miR-1298 mimics, si-circPDSS1+ miR-1298 inhibitor (anti-miR-1298) were transfected into liver cancer cell MHCC97H, respectively. Apoptosis was detected by flow cytometry, and cell migration and invasion were detected by transwell assays. Results Compared with adjacent tissues, the expression of circPDSS1 in liver cancer tissues was significantly increased (3.41±0.33 vs 1.00±0.06), while the expression of miR-1298 was significantly reduced (0.42±0.04 vs 1.00±0.07, P<0.05). circPDSS1 targeted and negatively regulated miR-1298 expression. After inhibiting the expression of circPDSS1, the apoptosis rate of MHCC97H cells was significantly increased (22.71±2.19% vs 6.02±0.05%), while the number of migrating (55.72±4.78 vs 101.86±9.65) and invasive (41.24±3.80 vs 85.71±7.57) cells were significantly decreased (P<0.05). After overexpression of miR-1298, the apoptosis rate of MHCC97H cells was significantly increased (18.67±1.06% vs 7.08±0.69%), while the cell numbers of migrating (61.11±5.54 vs 107.15±10.96) and invading (50.05±4.22 vs 88.57±7.96) were significantly decreased (P<0.05). Compared with the inhibition of circPDSS1, the apoptosis rate (11.68±1.24% vs 23.31±2.84%) of MHCC97H after the inhibition of miR-1298 and circPDSS1 was significantly decreased, while the cell numbers of migrating (86.59±7.44 vs 54.59±4.78) and invading (76.01±6.33 vs 39.91±3.73) were significantly increased (P<0.05). Conclusion Inhibiting the expression of circPDSS1 can reduce the migration and invasion ability of liver cancer cells and induce apoptosis. The mechanism is related to the targeted regulation of miR-1298.

Key words: circPDSS1, liver cancer, migration and invasion, apoptosis, miR-1298

李敏, 吴兴桂, 朱军华. circPDSS1通过靶向miR-1298调控肝癌细胞侵袭、迁移和凋亡的分子机制[J]. 肝脏, 2021, 26(9): 1011-1015.

LI Min, WU Xing-gui, ZHU Jun-hua. circPDSS1 regulates the invasion, migration and apoptosis of hepatocellular carcinoma cells by targeting miR-1298[J]. Chinese Hepatolgy, 2021, 26(9): 1011-1015.

参考文献

[1] Kim NG, Nguyen PP, Dang H, et al. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: a real-world experience from 1998 to 2015. Cancer, 2018, 124: 2588-2598.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391: 1301-1314.
[3] Vo JN, Cieslik M, Zhang Y, et al. The Landscape of Circular RNA in Cancer. Cell, 2019, 176: 869-881.
[4] Kristensen LS, Hansen TB, Ven? MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene, 2018, 37: 555-565.
[5] Ouyang Y, Li Y, Huang Y, et al. CircRNA circPDSS1 promotes the gastric cancer progression by sponging miR-186-5p and modulating NEK2. J Cell Physiol, 2019, 234: 10458-10469.
[6] Qiu ZK, Liu N, Zhao SF, et al. MiR-1298 expression correlates with prognosis and inhibits cell proliferation and invasion of gastric cancer. Eur Rev Med Pharmacol Sci, 2018, 22: 1672-1679.
[7] Du Z, Wu J, Wang J, et al. MicroRNA-1298 is downregulated in non-small cell lung cancer and suppresses tumor progression in tumor cells. Diagn Pathol, 2019, 14: 132-137.
[8] Yu Q, Liu P, Han G, et al. CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16. Biosci Rep, 2020, 40: BSR20191961.
[9] Wang X, Yang B, She Y, et al. The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem, 2018, 119: 7790-7799.
[10] Wang R, Ke ZF, Wang F, et al. GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem, 2015, 35: 969-982.
[11] Yu J, Xu QG, Wang ZG, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol, 2018, 68: 1214-1227.
[12] Zhou Y, Dang J, Chang KY, et al. miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. Cancer Res, 2016, 76: 5777-5787.
[13] Li G, Sun L, Mu Z, et al. MicroRNA-1298-5p inhibits cell proliferation and the invasiveness of bladder cancer cells via down-regulation of connexin 43. Biochem Cell Biol, 2020, 98: 227-237.

[1]	郭智辈, 唐文才, 李小华, 汤富强, 张尾兰. CT三维重建在原发性肝癌肝脏切除术前肿瘤体积评估中的应用[J]. 肝脏, 2021, 26(9): 1003-1006.
[2]	陈超, 姚玲, 邱邦东, 王小燕. GP73与铁调素在HBV相关性肝癌患者血清中表达变化及与预后的相关性[J]. 肝脏, 2021, 26(9): 1007-1010.
[3]	孙文文, 张凌云. 叶酸代谢通路基因在肝癌中的表达及意义[J]. 肝脏, 2021, 26(8): 851-856.
[4]	朱翊, 赵萍, 李杰珍, 冉博. 术前NLR水平与原发性肝癌患者肝切除术后肝衰竭的相关性[J]. 肝脏, 2021, 26(8): 857-860.
[5]	王开乐, 金贤德, 王甄, 张欣, 周杰. 多模态影像定量参数在肝硬化背景下小肝癌及增生结节的鉴别诊断价值[J]. 肝脏, 2021, 26(8): 861-865.
[6]	闾少冬, 魏勇鹏, 王卓, 袁建勇, 卢军华. Hippo信号通路中MST1和MST2的表达在肝癌干细胞干性维持和自我更新中的意义[J]. 肝脏, 2021, 26(8): 866-870.
[7]	袁溢苒, 陈龙, 张臻. miR-548a-5p靶向HMBOX1调控肝癌细胞HepG2的凋亡研究[J]. 肝脏, 2021, 26(8): 871-873.
[8]	侯亚萍, 张小晶, 李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系[J]. 肝脏, 2021, 26(7): 757-760.
[9]	吕发凯, 王登基, 谢钰辉, 张宇. 腹腔镜复杂性肝脏切除术中行CLCVP对肝癌患者围术期指标及预后的影响[J]. 肝脏, 2021, 26(7): 761-764.
[10]	艾俊, 张佳娟, 郑文凯, 李平. ABO血型与肝癌相关性的meta分析[J]. 肝脏, 2021, 26(7): 765-769.
[11]	何倩玉, 李俊峰, 毛小荣. 慢性HBV感染相关性肝癌发生的突变基因研究[J]. 肝脏, 2021, 26(7): 811-814.
[12]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. 阿帕替尼对中晚期肝癌患者TACE术后血管生成因子水平的影响[J]. 肝脏, 2021, 26(6): 628-631.
[13]	贾哲, 张珂, 黄容海, 赫嵘, 鲁岩, 蒋力. 肝癌合并肝硬化脾功能亢进患者的细胞免疫功能研究及临床意义[J]. 肝脏, 2021, 26(6): 632-637.
[14]	杨庆玺, 苏吉亮, 孙忠文, 刘元勋, 胡文娟. 21例肝癌合并脑梗死患者临床特点观察[J]. 肝脏, 2021, 26(6): 642-645.
[15]	李飞龙, 张子倩. 转移性肝癌合并肝性脑病短期内死亡风险的潜在影响因素研究[J]. 肝脏, 2021, 26(6): 646-649.